JAK2 V617F mutation is uncommon in non-Hodgkin lymphomas.
Recently, the JAK2 V617F mutation has been reported in high proportions of chronic myeloproliferative disorders, including polycythemia vera. To see whether the JAK2 V617F is important in the pathogenesis of lymphoid malignancies, this study analysed the occurrence of the JAK2 V617F mutation in 117 non-Hodgkin lymphomas (NHLs) by a single strand conformation polymorphism assay. However, there was no JAK2 V617F mutation in the NHLs and the data suggest that the JAK2 V617F mutation may not play a role in the development of NHL.
Lee
Jong Woo
JW
Department of Pathology, College of Medicine, The Catholic University of Korea, Seoul.
Soung
Young Hwa
YH
Kim
Su Young
SY
Nam
Suk Woo
SW
Park
Won Sang
WS
Lee
Jung Young
JY
Yoo
Nam Jin
NJ
Lee
Sug Hyung
SH
D019943:Amino Acid Substitution; D005091:Exons; D006801:Humans; D053614:Janus Kinase 2; D008228:Lymphoma, Non-Hodgkin / Q000235:genetics*; D009154:Mutation; D016133:Polymerase Chain Reaction; D018807:Polymorphism, Single-Stranded Conformational; D011505:Protein-Tyrosine Kinases / Q000235:genetics*; D011518:Proto-Oncogene Proteins / Q000235:genetics*
D011518:Proto-Oncogene Proteins; D011505:Protein-Tyrosine Kinases; C507924:JAK2 protein, human; D053614:Janus Kinase 2